Stage I pure seminoma testicular cancer represents the earliest stage of this disease, where cancer cells remain confined to the testicle itself without spreading to lymph nodes or distant organs. Treatment focuses on removing the affected testicle and deciding on the best follow-up approach to prevent recurrence while minimizing long-term side effects.

Understanding Treatment Goals in Early-Stage Disease

When someone receives a diagnosis of stage I pure seminoma, the primary treatment goal is to achieve a complete cure while preserving quality of life. At this earliest stage, the cancer is limited to the testicle, meaning it has not spread to nearby lymph nodes or other parts of the body. This localized disease offers an excellent opportunity for successful treatment with minimal intervention.^[1]

The treatment approach depends on several factors, including the size of the tumor within the testicle, the patient’s age, overall health, and personal preferences regarding follow-up schedules. Medical professionals consider whether the tumor has grown beyond the testicle into nearby structures, even though it remains classified as stage I as long as it hasn’t reached lymph nodes or distant organs.^[2]

One of the most important aspects of treating stage I seminoma is balancing the need to prevent cancer recurrence with the desire to avoid unnecessary treatments that could cause long-term complications. Because this cancer type is highly curable, doctors now focus not just on survival rates—which approach nearly 100% for early-stage seminoma—but also on minimizing treatment-related side effects that could affect patients for decades after their cancer is gone.^[3]

Medical societies and cancer organizations have established standard treatment recommendations based on decades of research and patient outcomes. These guidelines help doctors offer the most effective care while accounting for individual patient circumstances. At the same time, researchers continue to explore new approaches in clinical trials, seeking ways to reduce treatment burden while maintaining excellent cure rates.^[4]

Standard Treatment Approaches

The foundation of treatment for stage I pure seminoma begins with surgical removal of the affected testicle, a procedure called radical inguinal orchiectomy. This surgery is typically performed as part of the diagnostic process, allowing doctors to examine the tumor tissue and confirm the diagnosis. During the procedure, surgeons remove the entire testicle and spermatic cord through a small incision in the groin area. This surgical approach differs from accessing the testicle through the scrotum, as it helps prevent cancer cells from spreading through different lymphatic drainage pathways.^[7]

After surgery, doctors measure specific proteins in the blood called tumor markers. These include alpha-fetoprotein (AFP), beta-human chorionic gonadotropin (beta-hCG), and lactate dehydrogenase (LDH). Pure seminoma does not produce elevated AFP levels; if AFP is elevated, the tumor is treated as a mixed germ cell tumor even if the pathology shows pure seminoma. Some patients with stage I seminoma may have slightly elevated beta-hCG levels before surgery, which typically normalize after the testicle is removed. These markers play a crucial role in monitoring for cancer recurrence during follow-up.^[4]

Following surgical removal of the testicle, patients face three main management options: active surveillance, radiation therapy, or chemotherapy. The choice among these approaches depends on multiple factors and should be made through shared decision-making between the patient and their healthcare team.^[11]

Active Surveillance

Active surveillance has become the preferred approach for most men with stage I seminoma after surgery. This strategy involves regular and frequent monitoring to detect any signs of cancer recurrence without immediately administering additional treatment. The approach recognizes that only about 15% of stage I seminoma patients have microscopic cancer cells that have spread beyond the testicle, meaning the vast majority are cured by surgery alone.^[10]

During active surveillance, patients undergo scheduled follow-up visits that include physical examinations, blood tests to check tumor marker levels, and imaging studies such as CT scans of the abdomen and pelvis. The frequency of these visits is highest in the first few years after surgery, as this is when recurrence is most likely to occur—typically between 12 and 36 months after the initial treatment. If cancer returns during surveillance, treatment is initiated at that time, and the cure rate remains extremely high even for these late-treated recurrences.^[7]

One advantage of surveillance is that it allows patients to avoid the potential side effects of radiation or chemotherapy. However, it requires commitment to a long-term follow-up schedule and involves repeated exposure to radiation from CT scans. Some patients find the uncertainty of waiting and watching to be emotionally challenging, while others appreciate avoiding unnecessary treatment.^[10]

Radiation Therapy

Radiation therapy was the standard treatment for stage I seminoma for many years and remains an effective option, though it is now typically reserved for patients who cannot or will not comply with the demands of active surveillance. When used, radiation is directed at the retroperitoneal lymph nodes—the lymph nodes located at the back of the abdomen—which are the most common first site of cancer spread. Sometimes radiation is also given to lymph nodes in the pelvis.^[7]

The typical radiation dose for stage I seminoma is 20 Gray (Gy), though some centers use 25.5 Gy depending on specific circumstances. Treatment is usually delivered over several weeks, with small doses given each day. Radiation therapy is highly effective at preventing recurrence, with cure rates approaching 100% for stage I disease.^[11]

However, radiation therapy can cause both short-term and long-term side effects. Acute side effects during or shortly after treatment may include fatigue, nausea, and diarrhea, which typically resolve after treatment ends. More concerning are the potential long-term effects, including an increased risk of developing secondary cancers in the radiation field decades later, particularly cancers of the stomach, colon, or pancreas. Radiation can also increase the risk of cardiovascular disease, including heart attacks, especially when the radiation field includes areas near the heart. Because seminoma patients are typically young men with many decades of life ahead, these long-term risks have become increasingly important considerations in treatment planning.^[5]

Chemotherapy

Single-agent chemotherapy with carboplatin is another option for stage I seminoma after surgery. This approach typically involves one or two cycles of carboplatin given intravenously. Carboplatin is a platinum-based chemotherapy drug that works by damaging the DNA of cancer cells, preventing them from dividing and growing.^[7]

Adjuvant carboplatin therapy has been shown to be highly effective at reducing the risk of recurrence, with cancer-specific survival rates nearly identical to radiation therapy. Some studies suggest it may be slightly less effective than radiation at preventing relapse, but any recurrences that do occur can still be successfully treated, maintaining the overall excellent survival rate.^[10]

The side effects of carboplatin are generally less severe than those of multi-drug chemotherapy regimens used for more advanced disease. Common side effects include temporary drops in blood cell counts, fatigue, nausea, and temporary changes in kidney function. Most patients tolerate one or two cycles of carboplatin well. Long-term side effects appear to be less common and less severe than those associated with radiation therapy, particularly regarding cardiovascular disease and secondary cancers. However, there remains some concern about potential effects on hearing and kidney function, as well as a possible small increase in the risk of developing leukemia years later.^[5]

Carboplatin may be particularly recommended for patients with elevated tumor marker levels after surgery or for those who cannot commit to the intensive follow-up schedule required for surveillance. It represents a middle ground between the watch-and-wait approach of surveillance and the more intensive treatment of radiation therapy.^[7]

Risk-Adapted Treatment Strategies

Researchers have worked to identify factors that help predict which stage I seminoma patients are at higher risk for cancer recurrence. This has led to the development of risk-adapted treatment strategies, where the intensity of treatment or surveillance is adjusted based on individual risk factors.^[10]

The two main risk factors that have been identified are tumor size and invasion of the rete testis—a network of tubules in the testicle where sperm collects before entering the spermatic cord. Patients whose tumors are larger than 4 centimeters or whose tumors have invaded the rete testis are considered at higher risk for having microscopic disease that has spread beyond the testicle. These higher-risk patients have approximately a 30% chance of recurrence with surveillance alone, compared to about 12% for lower-risk patients.^[14]

In a risk-adapted approach, patients at low risk—those with tumors smaller than 4 centimeters and no rete testis invasion—might be offered surveillance as the strongly preferred option. Higher-risk patients might be counseled more toward adjuvant treatment with carboplatin or, less commonly now, radiation therapy. However, even high-risk patients can choose surveillance if they understand the increased likelihood of needing treatment later and are committed to close follow-up.^[10]

This personalized approach helps patients make informed decisions that align with their individual medical situation, personal preferences, and tolerance for risk and uncertainty. It acknowledges that there is no single “best” treatment for all patients with stage I seminoma, but rather several excellent options with different trade-offs.^[10]

Treatment in Clinical Trials

While standard treatments for stage I seminoma already achieve excellent outcomes, researchers continue to explore new approaches in clinical trials. The goals of this ongoing research include further reducing treatment-related side effects, simplifying follow-up schedules, and identifying better ways to predict which patients need additional treatment beyond surgery.^[4]

One area of investigation involves the role of retroperitoneal lymph node dissection (RPLND) for stage I seminoma. This surgical procedure involves removing the lymph nodes at the back of the abdomen where seminoma typically spreads first. While RPLND has been a standard part of treatment for non-seminoma germ cell tumors, it has not traditionally been used for pure seminoma because these tumors respond so well to radiation and chemotherapy.^[11]

Recent clinical trials have examined whether RPLND might be a useful option for highly selected stage I seminoma patients. The PRIMETEST trial, a Phase II study, evaluated this approach in 33 patients with early-stage disease. While the study did not meet its primary goal of preventing progression in a high percentage of patients, researchers suggested that surgery might benefit carefully chosen individuals. Another Phase II study in 55 patients showed better results, with about 81% of patients remaining cancer-free at two years after surgery. Patients who did experience recurrence were successfully treated with chemotherapy or additional surgery, and all were disease-free at last follow-up.^[11]

These surgical approaches are being studied because they might offer some patients an alternative to radiation therapy (avoiding its long-term side effects) or surveillance (avoiding the anxiety and repeated imaging). However, RPLND is major abdominal surgery with its own risks and potential complications, including injury to nerves that control ejaculation. The ongoing SEMS trial (Surgery in Early Metastatic Seminoma) continues to evaluate the role of surgery in early-stage seminoma patients.^[11]

Another focus of clinical research involves refining surveillance protocols to reduce the burden of follow-up while maintaining excellent cancer detection rates. Researchers are investigating whether certain patients might safely undergo less frequent imaging or whether newer imaging techniques could reduce radiation exposure from repeated CT scans. Some studies are exploring the use of MRI scans instead of CT scans for follow-up, as MRI does not involve radiation exposure, though it is more expensive and less widely available.^[10]

Scientists are also working to identify biomarkers—measurable substances in blood or tissue that could help predict which patients are at risk for recurrence. Better predictive tools could allow doctors to recommend more personalized treatment plans, directing more aggressive therapy only to those who truly need it while sparing others from unnecessary treatment.^[4]

Clinical trials examining modifications to standard carboplatin regimens are ongoing. Researchers are studying whether different dosing schedules or combinations with other less toxic agents might improve outcomes or reduce side effects. However, because cure rates are already so high with current treatments, any new approach must prove it can maintain these excellent results while offering clear advantages in terms of reduced toxicity or improved convenience.^[10]

Patients interested in participating in clinical trials should discuss available options with their treatment team. Participation in research studies contributes to advancing medical knowledge and improving future treatments while often providing access to cutting-edge care. However, not all patients will be eligible for clinical trials based on specific inclusion criteria, and standard treatments remain highly effective.^[4]

Most Common Treatment Methods

• Surgery (Radical Inguinal Orchiectomy)
  • Surgical removal of the affected testicle and spermatic cord through an incision in the groin
  • Performed both for diagnosis and as the primary treatment for stage I seminoma
  • Does not affect sexual function or the ability to father children if one testicle remains
  • Cure rates approach 85% with surgery alone, without additional treatment^[7]
• Active Surveillance
  • Regular monitoring with physical exams, blood tests for tumor markers, and CT imaging
  • Preferred approach for most stage I seminoma patients after surgery
  • Follow-up is most intensive in the first 2-3 years when recurrence is most likely
  • Avoids side effects of radiation or chemotherapy but requires long-term commitment to follow-up^[7]
• Radiation Therapy
  • External beam radiation directed at retroperitoneal and sometimes pelvic lymph nodes
  • Typical dose is 20-25.5 Gray delivered over several weeks
  • Highly effective at preventing recurrence but carries risks of long-term side effects
  • Potential complications include increased risk of secondary cancers and cardiovascular disease decades later
  • Now reserved for patients unable to comply with surveillance requirements^[5]
• Chemotherapy with Carboplatin
  • One or two cycles of single-agent carboplatin given intravenously
  • Reduces risk of recurrence with generally manageable side effects
  • Side effects may include temporary blood count changes, fatigue, and nausea
  • Appears to have fewer long-term risks than radiation therapy
  • Recommended for patients with elevated tumor markers or inability to maintain surveillance schedule^[7]
• Risk-Adapted Management
  • Treatment decisions based on tumor size and rete testis invasion
  • Low-risk patients (tumor under 4 cm, no rete testis invasion) strongly encouraged toward surveillance
  • Higher-risk patients may be offered carboplatin chemotherapy or radiation therapy
  • Personalizes treatment approach based on individual recurrence risk^[14]